In this study, the authors report a potent neutralizing antibody targeting a conserved epitope within RSV pre-F that shows higher antiviral activity against both RSV-A and -B subgroups in vitro and in small animal models than FDA-approved prophylactic agents.
- Yongpeng Sun
- Liqin Liu
- Ningshao Xia